Great Hill Capital LLC Acquires 126,680 Shares of DENTSPLY SIRONA Inc. $XRAY

Key Points

• Great Hill Capital increased its DENTSPLY SIRONA stake by 7.8% in the third quarter, purchasing 126,680 additional shares and bringing its holdings to 1.75 million shares valued at approximately $15.5 million.
• DENTSPLY SIRONA recently traded at $8.87, near its 52-week low, with a $1.77 billion market capitalization. Its latest quarterly results beat expectations, reporting $0.52 in EPS and $898 million in revenue, though revenue declined 4.1% year over year.
• Analyst sentiment remains cautious: the stock has a consensus “Hold” rating and a $12.92 average price target, with several firms recently lowering their targets.

Great Hill Capital LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 7.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,749,065 shares of the medical instruments supplier's stock after purchasing an additional 126,680 shares during the period. DENTSPLY SIRONA makes up about 1.0% of Great Hill Capital LLC's holdings, making the stock its 10th biggest holding. Great Hill Capital LLC owned approximately 0.88% of DENTSPLY SIRONA worth $15,497,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Blue Trust Inc. lifted its stake in DENTSPLY SIRONA by 10.8% in the first quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier's stock worth $146,000 after purchasing an additional 1,226 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in DENTSPLY SIRONA by 3.3% during the first quarter. Oregon Public Employees Retirement Fund now owns 40,944 shares of the medical instruments supplier's stock valued at $475,000 after buying an additional 1,300 shares during the period. Allworth Financial LP grew its stake in shares of DENTSPLY SIRONA by 163.8% during the second quarter. Allworth Financial LP now owns 4,815 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 2,990 shares during the last quarter. Nykredit A S bought a new position in shares of DENTSPLY SIRONA during the second quarter valued at about $38,000. Finally, IFP Advisors Inc grew its stake in shares of DENTSPLY SIRONA by 244.4% during the third quarter. IFP Advisors Inc now owns 5,566 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 3,950 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Trading Up 5.3%

NASDAQ XRAY opened at $8.87 on Wednesday. DENTSPLY SIRONA Inc. has a fifty-two week low of $8.32 and a fifty-two week high of $14.76. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The stock has a 50 day simple moving average of $10.00 and a two-hundred day simple moving average of $10.99. The stock has a market cap of $1.77 billion, a P/E ratio of 5.89, a price-to-earnings-growth ratio of 1.07 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The company had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the prior year, the company earned $0.52 earnings per share. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts forecast that DENTSPLY SIRONA Inc. will post 1.39 earnings per share for the current year.

Analysts Set New Price Targets

XRAY has been the topic of several analyst reports. Piper Sandler decreased their price objective on DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Friday, October 9th. Barrington Research set a $15.00 target price on DENTSPLY SIRONA in a report on Monday, August 10th. Leerink Partners reduced their price target on DENTSPLY SIRONA from $14.00 to $10.00 and set a "market perform" rating on the stock in a research report on Wednesday, October 14th. Barclays raised their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an "underweight" rating in a research report on Monday, August 24th. Finally, BMO Capital Markets decreased their price target on DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research note on Thursday, September 17th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $12.92.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.